HOME
PRODUCT
SOLUTION
SUPPORT
SHOP
ABOUT
CONTACT
Antibody–drug conjugates (ADCs) are transforming precision oncology by combining the specificity of monoclonal antibodies with the cytotoxic power of small-molecule drugs. By selectively delivering potent payloads to tumor cells, ADCs aim to maximize antitumor efficacy while minimizing systemic toxicity.
Expert reveal: mIHC + AI fixes 5 critical IHC flaws. Discover 2025's game-changing pathology tech in minutes!
3-minute expert guide: Boost cancer research with mIHC + spatial transcriptomics. 2025's top spatial biology techniques!